Position in PTGX
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$1,462,501
-$1,011,552 QoQ
Shares Held
11,931
-49.2% QoQ
Ownership
0.018%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#161
of 341 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 98%
Shared 0%
None 2%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Calamos Advisors LLC holds $119,502,354 across 21 Biotechnology names. PTGX ranks #13 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
75,388 | $37,447,481 | |
| 2 | RPRX |
Royalty Pharma plc
|
573,521 | $32,157,322 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
11,578 | $7,219,346 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
22,435 | $7,091,478 | |
| 5 | TVTX |
Travere Therapeutics, Inc.
|
121,755 | $6,916,901 | |
| 6 | CYTK |
Cytokinetics Inc
|
51,443 | $4,382,428 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
19,711 | $3,691,476 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
14,699 | $3,597,874 |
All Filings in PTGX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,462,501 | 11,931 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $2,474,053 | 23,473 | Shares | Other | 2026-05-04 | |
| No filing history on record for this holder in this stock. | ||||||